1
|
Afjadi MN, Dabirmanesh B, Uversky VN. Therapeutic approaches in proteinopathies. PROGRESS IN MOLECULAR BIOLOGY AND TRANSLATIONAL SCIENCE 2024; 206:341-388. [PMID: 38811085 DOI: 10.1016/bs.pmbts.2024.03.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2024]
Abstract
A family of maladies known as amyloid disorders, proteinopathy, or amyloidosis, are characterized by the accumulation of abnormal protein aggregates containing cross-β-sheet amyloid fibrils in many organs and tissues. Often, proteins that have been improperly formed or folded make up these fibrils. Nowadays, most treatments for amyloid illness focus on managing symptoms rather than curing or preventing the underlying disease process. However, recent advances in our understanding of the biology of amyloid diseases have led to the development of innovative therapies that target the emergence and accumulation of amyloid fibrils. Examples of these treatments include the use of small compounds, monoclonal antibodies, gene therapy, and others. In the end, even if the majority of therapies for amyloid diseases are symptomatic, greater research into the biology behind these disorders is identifying new targets for potential therapy and paving the way for the development of more effective treatments in the future.
Collapse
Affiliation(s)
- Mohsen Nabi Afjadi
- Department of Biochemistry, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran
| | - Bahareh Dabirmanesh
- Department of Biochemistry, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran
| | - Vladimir N Uversky
- Pushchino Scientific Center for Biological Research of the Russian Academy of Sciences, Institute for Biological Instrumentation, Pushchino, Moscow, Russia; Department of Molecular Medicine and USF Health Byrd Alzheimer's Research Institute, Morsani College of Medicine, University of South Florida, Tampa, FL, United States.
| |
Collapse
|
2
|
Fong VH, Wong S, Jintaridhi P, Vieira A. Transport of the Thyroid Hormone Carrier Protein Transthyretin into Human Epidermoid Cells. Endocr Res 2020; 45:131-136. [PMID: 31762320 DOI: 10.1080/07435800.2019.1694538] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
Purpose: Transthyretin (TTR) is a protein with a growing number of biological functions in addition to its well-established binding and circulatory transport of thyroxine, and indirect retinoid transport through interaction with retinol-binding protein. Misfolded and aggregated wild-type and mutant TTRs are involved in amyloid diseases. Several aspects of TTR pathology and physiology remain poorly understood. Receptor-mediated cellular transport of TTR has been described in a few cell types; and such studies suggest the possibility of different TTR receptors and endocytic pathways. Our main objective was to further understand the endocytic pathways for TTR.Methods: In the current study, analyses of TTR endocytic transport were performed in the human A431 cell line. The results of TTR uptake were compared with those of the iron-carrier protein transferrin (Tf, a common stardard for endocytosis studies) in the same cell types.Results: A comparison of TTR and Tf endocytosis suggested similar early, 5-10 min, accumulation kinetics. But at a later time, 30 min, TTR accumulation was 20-30% lower than that of Tf (p < .05), a result that suggests different post-endocytic fates for these two ligands. Through the use of multiple endocytosis inhibitors, biochemical evidence is provided for an internalization pathway that differs from the clathrin-mediated endocytosis of Tf.Conclusions: These results for A431 cells are compared with others reported for different cell types; and it is suggested that this same hormone carrier protein can transit into cells through multiple endocytic pathways.
Collapse
Affiliation(s)
- Vai Hong Fong
- Biomedical Physiology BPK, Simon Fraser University, Burnaby, BC, Canada
- Department of Neurology, Far Eastern Memorial University Hospital, New Taipei City, Taiwan
| | - Shaun Wong
- Biomedical Physiology BPK, Simon Fraser University, Burnaby, BC, Canada
| | | | - Amandio Vieira
- Biomedical Physiology BPK, Simon Fraser University, Burnaby, BC, Canada
| |
Collapse
|
3
|
Castaño A, DeLuca A, Weinberg R, Pozniakoff T, Blaner WS, Pirmohamed A, Bettencourt B, Gollob J, Karsten V, Vest JA, Chiuzan C, Maurer MS, Bokhari S. Serial scanning with technetium pyrophosphate ( 99mTc-PYP) in advanced ATTR cardiac amyloidosis. J Nucl Cardiol 2016; 23:1355-1363. [PMID: 26453570 PMCID: PMC4826633 DOI: 10.1007/s12350-015-0261-x] [Citation(s) in RCA: 74] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2015] [Accepted: 07/26/2015] [Indexed: 12/25/2022]
Abstract
BACKGROUND Development of noninvasive imaging modalities to quantify amyloid burden over time is an unmet clinical need. Technetium pyrophosphate (99mTc-PYP) scintigraphy is a simple and widely available radiotracer useful to differentiate transthyretin from light-chain amyloidosis in patients with advanced cardiac amyloidosis. We examined the utility of serial 99mTc-PYP scanning to quantify amyloid burden over time in TTR cardiac amyloidosis (ATTR-CA). METHODS AND RESULTS Twenty subjects with ATTR-CA (10 wild type, 10 mutant) underwent serial 99mTc-PYP planar cardiac imaging. Cardiac retention was assessed both semiquantitatively (visual score 0, no uptake to 3, uptake greater than bone) and quantitatively (region of interest drawn over the heart, copied, and mirrored over the contralateral chest) to calculate a heart-to-contralateral (H/CL) ratio. Index scan mean visual score and H/CL were 3.0 ± 0.2 and 1.79 ± 0.2, respectively, and after an average 1.5 ± 0.5 years follow-up, did not differ, 3.0 ± 0.2, P = .33 and 1.76 ± 0.2, P = .44. H/CL change was minimal, 0.03 ± 0.17, did not correlate with time between scans, r = 0.19, P = .43, and was observed despite obvious clinical progression (increase in troponin ≥ 0.1 ng/mL, BNP ≥ 400 pg/mL, NYHA class, and/or death). CONCLUSIONS Serial 99mTc-PYP scanning in subjects with advanced ATTR-CA does not show significant changes over an average 1.5 years of follow-up despite obvious clinical progression.
Collapse
Affiliation(s)
- Adam Castaño
- Nuclear Cardiology Laboratory, Columbia College of Physicians & Surgeons, 622 W 168th St. P.H. 10-203, New York, NY, 10032, USA.
- Division of Cardiology, Center for Advanced Cardiac Care, Columbia College of Physicians & Surgeons, New York, NY, USA.
| | - Albert DeLuca
- Nuclear Cardiology Laboratory, Columbia College of Physicians & Surgeons, 622 W 168th St. P.H. 10-203, New York, NY, 10032, USA
| | - Richard Weinberg
- Nuclear Cardiology Laboratory, Columbia College of Physicians & Surgeons, 622 W 168th St. P.H. 10-203, New York, NY, 10032, USA
| | - Ted Pozniakoff
- Nuclear Cardiology Laboratory, Columbia College of Physicians & Surgeons, 622 W 168th St. P.H. 10-203, New York, NY, 10032, USA
| | - William S Blaner
- Department of Medicine, Institute of Human Nutrition, Columbia College of Physicians & Surgeons, New York, NY, USA
| | - Altaf Pirmohamed
- Nuclear Cardiology Laboratory, Columbia College of Physicians & Surgeons, 622 W 168th St. P.H. 10-203, New York, NY, 10032, USA
| | | | | | | | | | - Codruta Chiuzan
- Mailman School of Public Health, Columbia College of Physicians & Surgeons, New York, NY, USA
| | - Mathew S Maurer
- Division of Cardiology, Center for Advanced Cardiac Care, Columbia College of Physicians & Surgeons, New York, NY, USA
| | - Sabahat Bokhari
- Nuclear Cardiology Laboratory, Columbia College of Physicians & Surgeons, 622 W 168th St. P.H. 10-203, New York, NY, 10032, USA
| |
Collapse
|
4
|
Pires RH, Saraiva MJ, Damas AM, Kellermayer MSZ. Force spectroscopy reveals the presence of structurally modified dimers in transthyretin amyloid annular oligomers. J Mol Recognit 2016; 30. [PMID: 27808434 DOI: 10.1002/jmr.2587] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2016] [Revised: 09/21/2016] [Accepted: 09/30/2016] [Indexed: 12/17/2022]
Abstract
Toxicity in amyloidogenic protein misfolding disorders is thought to involve intermediate states of aggregation associated with the formation of amyloid fibrils. Despite their relevance, the heterogeneity and transience of these oligomers have placed great barriers in our understanding of their structural properties. Among amyloid intermediates, annular oligomers or annular protofibrils have raised considerable interest because they may contribute to a mechanism of cellular toxicity via membrane permeation. Here we investigated, by using AFM force spectroscopy, the structural detail of amyloid annular oligomers from transthyretin (TTR), a protein involved in systemic and neurodegenerative amyloidogenic disorders. Manipulation was performed in situ, in the absence of molecular handles and using persistence length-fit values to select relevant curves. Force curves reveal the presence of dimers in TTR annular oligomers that unfold via a series of structural intermediates. This is in contrast with the manipulation of native TTR that was more often manipulated over length scales compatible with a TTR monomer and without unfolding intermediates. Imaging and force spectroscopy data suggest that dimers are formed by the assembly of monomers in a head-to-head orientation with a nonnative interface along their β-strands. Furthermore, these dimers stack through nonnative contacts that may enhance the stability of the misfolded structure.
Collapse
Affiliation(s)
- Ricardo H Pires
- Department of Biophysics and Radiation Biology, Semmelweis University, Budapest, Hungary.,Institute for Molecular and Cell Biology (IBMC), Porto, Portugal
| | - Maria J Saraiva
- Institute for Molecular and Cell Biology (IBMC), Porto, Portugal.,Instituto de Ciências Biomédicas de Abel Salazar (ICBAS), Universidade do Porto, Porto, Portugal
| | - Ana M Damas
- Institute for Molecular and Cell Biology (IBMC), Porto, Portugal.,Instituto de Ciências Biomédicas de Abel Salazar (ICBAS), Universidade do Porto, Porto, Portugal
| | - Miklós S Z Kellermayer
- Department of Biophysics and Radiation Biology, Semmelweis University, Budapest, Hungary.,MTA-SE Molecular Biophysics Research Group, Budapest, Hungary
| |
Collapse
|
5
|
Wan C, Allen TM, Cullis PR. Lipid nanoparticle delivery systems for siRNA-based therapeutics. Drug Deliv Transl Res 2015; 4:74-83. [PMID: 25786618 DOI: 10.1007/s13346-013-0161-z] [Citation(s) in RCA: 124] [Impact Index Per Article: 13.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
Therapeutics based on small interfering RNA (siRNA) have a huge potential for the treatment of disease but requires sophisticated delivery systems for in vivo applications. Lipid nanoparticles (LNP) are proven delivery systems for conventional small molecule drugs with over eight approved LNP drugs. Experience gained in the clinical development of LNP for the delivery of small molecules, combined with an understanding of the physical properties of lipids, can be applied to design LNP systems for in vivo delivery of siRNA. In particular, cationic lipids are required to achieve efficient encapsulation of oligonucleotides; however, the presence of a charge on LNP systems can result in toxic side effects and rapid clearance from the circulation. To address these problems, we have developed ionizable cationic lipids with pKa values below 7 that allow oligonucleotide encapsulation at low pH (e.g., pH 4) and a relatively neutral surface at physiological pH. Further optimization of cationic lipids to achieve maximized endosomal destabilization following uptake has resulted in LNP siRNA systems that can silence genes in hepatocytes at doses as low as 0.005 mg siRNA/kg body weight in mouse models. These systems have been shown to be highly effective clinically, with promising results for the treatment of hypercholesterolemia and transthyretin-induced amyloidosis among others. More LNP siRNA therapeutics, targeting different tissues and diseases, are expected to become available in the near future.
Collapse
Affiliation(s)
- C Wan
- Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, Canada,
| | | | | |
Collapse
|